For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Healing & Recovery

Teriparatide

Also known as: PTH 1-34, Parathyroid Hormone (1-34), rhPTH(1-34), Forteo, Bonsity

fda approved

Recombinant human parathyroid hormone fragment consisting of the biologically active N-terminal 34 amino acids of endogenous PTH (PTH 1-34). It is a PTH1 receptor (PTH1R) agonist; when administered as a once-daily intermittent injection it preferentially stimulates osteoblast-mediated bone formation, increasing bone mineral density and reducing fracture risk. Teriparatide is FDA-approved (originally as Forteo, approved 2002) for osteoporosis at high fracture risk in postmenopausal women, men, and glucocorticoid-induced osteoporosis, and was the first anabolic (bone-building) osteoporosis therapy. It is one of the few peptides in this directory with full FDA marketing approval.

Common research uses

treatment of osteoporosis at high fracture risk (FDA-approved)glucocorticoid-induced osteoporosis (FDA-approved)off-label investigational use in fracture healing and bone defects
Real-time market data

Pricing for Teriparatide

Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.

No sellers for Teriparatide are indexed yet — we add vendors and their prices as we find them.